17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Inclusion Criteria:

Histologically confirmed diagnosis of solid tumor or leukemia with documented M3 marrow

Histologic confirmation of intrinsic brain stem tumors not required
Relapsed or refractory disease
No known curative therapy
In patients with CNS tumors, neurologic deficits must be stable for at least the past week
Performance status - Karnofsky 50-100% (>10 years of age)
Performance status - Lansky 50-100% (≤ 10 years of age)

For patients with solid tumors:

Absolute neutrophil count ≥ 1,000/mm^3
Platelet count ≥ 100,000/mm^3 (transfusion independent)
Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)

For patients with leukemia:

Platelet count ≥ 20,000/mm^3 (may receive platelet transfusions)
Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)
Bilirubin ≤ 1.5 times upper limit of normal (ULN)
ALT ≤ 2.5 times ULN
Albumin ≥ 2 g/dL
Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min

Creatinine based on age as follows:

≤ 0.8 mg/dL if ≤ 5 years of age
≤ 1.0 mg/dL if > 5 years and ≤ 10 years of age
≤ 1.2 mg/dL if > 10 years and ≤ 15 years of age
≤ 1.5 mg/dL if > 15 years and ≤ 21 years of age
No uncontrolled infection
No prior severe allergy to eggs
No situation that would preclude study participation
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
At least 7 days (or window for adverse effects has passed) since prior biologic therapy and recovered
At least 7 days since prior hematopoietic growth factors
At least 2 months since prior stem cell transplantation and no evidence of graft-vs-host disease
No concurrent hematopoietic growth factors
No concurrent biologic therapy
No concurrent immunotherapy
At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered
No other concurrent chemotherapy
No concurrent steroid therapy
At least 2 weeks since prior local palliative radiotherapy (small port)
At least 3 months since prior total body irradiation or craniospinal radiotherapy
At least 3 months since prior radiotherapy to ≥ 50% of the pelvis
At least 6 weeks since prior substantial bone marrow radiotherapy
Recovered from prior radiotherapy
No concurrent radiotherapy
No other concurrent investigational drugs
No other concurrent anticancer agents
No concurrent phenytoin or phenobarbital
No concurrent warfarin